Osteogenic PTHs and vascular ossification—Is there a danger for osteoporotics?
- 1 June 2005
- journal article
- review article
- Published by Wiley in Journal of Cellular Biochemistry
- Vol. 95 (3) , 437-444
Abstract
Inflammation in vascular (mostly arterial) walls and heart valves triggered by the trans‐endothelial influx of LDL particles and the action of subsequently modified (e.g., by oxidation) LDL particles can trigger true bone formation by valvar fibroblasts, by a subpopulation of re‐differentiation‐competent VSMCs (vascular smooth muscle cells) or by vascular pericytes. Vascular ossification can lead to heart failure and death. Elderly osteoporotic women who need osteogenic drugs to restore their lost skeletal bone are paradoxically prone to vascular ossification—the “calcification paradox.” The recent introduction into the clinic of a potently osteogenic parathyroid hormone peptide, Lilly's rhPTH‐(1–34)OH (Forteo™), to reverse skeletal bone loss raises the question of whether this and other potently osteogenic PTHs still in clinical trial might also stimulate vascular ossification in such osteoporotic women. Indeed the VSMCs in human and rat atherosclerotic lesions hyperexpress PTHrP and the PTHR1 (or PTH1R) receptor as do maturing osteoblasts. And the evidence indicates that endogenous PTHrP with its NLS (nuclear/nucleolar localization sequence) does stimulate VSMC proliferation (a prime prerequisite for atheroma formation and ossification) via intranuclear targets that inactivate pRb, the inhibitory G1/S checkpoint regulator, by stimulating its hyperphosphorylation. But neither externally added full‐length PTHrP nor the NLS‐lacking PTHrP‐(1–34)OH gets into the VSMC nucleus and instead they inhibit proliferation and calcification by only activating the cell's PTHR1 receptors. No PTH has an NLS and, as expected from the observations on the externally added PTHrPs, hPTH‐(1–34)OH inhibits calcification by VSMCs and cannot stimulate vascular ossification in a diabetic mouse model. Encouraging though this may be for osteoporotics with their “calcification paradox,” more work is needed to be sure that the skeletally osteogenic PTHs do not promote vascular ossification with its cardiovascular consequences.Keywords
This publication has 57 references indexed in Scilit:
- The serum level of bone-specific alkaline phosphatase activity is associated with aortic calcification in osteoporosis patientsJournal of Bone and Mineral Metabolism, 2004
- Parathyroid Hormone–Related Protein as a Regulator of pRb and the Cell Cycle in Arterial Smooth MuscleCirculation, 2004
- Vascular smooth muscle cells and calcification in atherosclerosisAmerican Heart Journal, 2004
- Mineral Exploration: Search for the Mechanism of Vascular Calcification and BeyondArteriosclerosis, Thrombosis, and Vascular Biology, 2003
- Possible Role of Parathyroid Hormone–Related Protein as a Proinflammatory Cytokine in AtherosclerosisStroke, 2003
- Inflammation in atherosclerosisNature, 2002
- Bone Formation in Carotid PlaquesStroke, 2002
- 1,25-Dihydroxyvitamin D3 as Well as Its Analogue OCT Lower Blood Calcium Through Inhibition of Bone Resorption in Hypercalcemic Rats with Continuous Parathyroid Hormone–Related Peptide InfusionJournal of Bone and Mineral Research, 2000
- Cyclization by a Specific Lactam Increases the Ability of Human Parathyroid Hormone (hPTH)-(1–31)NH2 to Stimulate Bone Growth in Ovariectomized RatsJournal of Bone and Mineral Research, 1997
- Coronary Atherosclerotic Smooth Muscle Cells Overexpress Human Parathyroid Hormone-Related PeptidesBiochemical and Biophysical Research Communications, 1994